Clinical trials: Major Bleeding
Brain Injuries
Tranexamic Acid for Preventing Progressive Intracranial Haemorrhage in Traumatic Brain Injury
The study's objective is to evaluate the effectiveness and safety of tranexamic acid for adult patients with moderate to severe TBI.With the research question as "Does TXA reduce the incidence of progressive intracranial…
- Trial name
- NCT00755209
- Testing
- tranexamic acid
- Where
- Thailand
- Volunteers
- 238 people
- Sponsor
- Khon Kaen University
Severe Forms of Hemophilia, Other Constitutional Bleeding Disorders
Input of a Multidisciplinary Device to Accompany the Announce of Diagnosis for Young Children With Serious Constitutional Hemorrhagic Disease and Their Families
Severe forms of hemophilia and other constitutional bleeding disorders represent a group of rare diseases. In last decades, news therapies have dramatically increased life expectancy and joint's protection.
- Trial name
- ACADHEM (NCT02834130)
- Testing
- Evaluation of psychological and psychopathological
- Where
- France
- Volunteers
- 30 people
- Sponsor
- Assistance Publique Hopitaux De Marseille
Hemophilia A
BAX 855 Continuation
To continue the evaluation of the safety and efficacy of BAX 855 for prophylaxis and treatment of bleeding episodes in adult and pediatric previously treated patients (PTPs) aged ≤ 75 years of age with severe hemophilia A.
- Trial name
- NCT01945593
- Testing
- BAX855
- Where
- 89 sites in United States, Australia and 21 more
- Volunteers
- 218 people
- Sponsor
- Baxalta now part of Shire
Severe Hemophilia A Without Inhibitor, Joint Bleed
Comparison of Outcomes Between Low Dose Emicizumab and Factor VIII in Clinically Severe Hemophilia A
To outcome between low dose Emicizumab and low dose prophylaxis with FVIII concentration To study pharmacokinetic, side effect of low dose Emicizumab
- Trial name
- NCT06155955
- Testing
- "Emicizumab", "HEMLIBRA®"
- Where
- Thailand
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Chulalongkorn University
Hemophilia A
Platelet Function in Patients With Hemophilia A
Abnormalities in the gene encoding Factor VIII (FVIII) results in hemophilia A, an X-linked recessive bleeding disorder with a prevalence of 1 in 5000 males.
- Trial name
- NCT02093065
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Boston Children's Hospital
Trauma Injury
Early Use of Cryoprecipitate With Major Hemorrhage Protocol (MHP) Activation
The purpose of this trial is to compare standard of care (SOC) massive transfusion protocol to SOC massive transfusion protocol plus early use of cryoprecipitate (within 90 minutes of emergency department arrival).
- Trial name
- NCT04704869
- Testing
- Cryoprecipitate, Red Blood Cells, Plasma
- Where
- 25 sites in United States, United Kingdom
- Volunteers
- 1,604 people
- Sponsor
- Bryan Cotton
Trauma, Hemorrhage
Fibrinogen Early In Severe Trauma studY Junior
1. Haemorrhage in severe trauma is a significant cause of mortality and is potentially the most preventable cause of death in paediatric trauma patients 2.
- Conditions
- Trauma, Hemorrhage, Coagulopathy, Pediatrics
- Trial name
- FEISTY Jnr (NCT03508141)
- Testing
- Fibrinogen Concentrate, Cryoprecipitate
- Where
- 10 sites in Australia
- Volunteers
- 44 people
- Sponsor
- Gold Coast Hospital and Health Service
Severe Hereditary Factor VIII Deficiency Disease Without Inhibitor, Moderate Hereditary Factor VIII Deficiency Disease Without Inhibitor
An Observational Study to Evaluate Physical Activity, Bleeding Incidence and Health Related Quality of Life, in Participants With Haemophilia A Without Inhibitors Receiving Standard of Care Treatment
This multicenter, non-interventional, prospective study will collect information about activity status, bleeds, health-related quality of life (HRQoL), health status, and safety in participants with moderate or severe haemophilia…
- Conditions
- Severe Hereditary Factor VIII Deficiency Disease Without Inhibitor, Moderate Hereditary Factor VIII Deficiency Disease Without Inhibitor, Haemophilia A
- Trial name
- POWER (NCT04165135)
- Testing
- Standard of Care for Haemophilia A
- Where
- 17 sites in Italy
- Volunteers
- 103 people
- Sponsor
- Hoffmann-La Roche
Abdominal Injuries, Wounds and Injuries
Predictors of In-Hospital Mortality in Severe Abdominal Trauma
Severe abdominal trauma is a leading cause of early death from bleeding and of later death from sepsis and organ failure. Clinicians use scoring systems to estimate the risk of dying, but most of these scores were developed and…
- Conditions
- Abdominal Injuries, Wounds and Injuries, Wounds, Nonpenetrating, Wounds, Penetrating
- Trial name
- NCT07843628
- Where
- Egypt
- Volunteers
- 430 people
- Sponsor
- Minia University
Hemophilia A
Prophylaxis Versus on Demand Treatment for Children With Hemophilia A
Comparison of the effect of three times a week prophylaxis on all bleeds with on-demand treatment for children with severe Hemophilia A.
- Trial name
- NCT01810666
- Testing
- Recombinant Factor VIII (Kogenate FS, BAY14-2222)
- Where
- 5 sites in China
- Volunteers
- 30 people
- Sponsor
- Bayer
Extreme Prematurity, Intraventricular Hemorrhage
Single-dose Prophylactic INdomethacin in Extremely Preterm Infants
In Canada, about 900 babies each year are born very early (<26 weeks of gestation) and have a high chance of dying or having a serious bleed in the brain.
- Conditions
- Extreme Prematurity, Intraventricular Hemorrhage, Morbidity;Newborn
- Trial name
- SPIN (NCT06572917)
- Testing
- Indomethacin
- Where
- 15 sites in United States, Australia and 1 more
- Volunteers
- 500 people
- Sponsor
- University of British Columbia
Extracorporeal Life Support, Extracorporeal Membrane Oxygenation
Quality Improvement to Reduce Mortality or Severe Intracranial Hemorrhage in Neonatal Extracorporeal Life Support
This is a three-year pre- and post- interventional study to assess the effectiveness of collaborative quality improvement interventions on reducing mortality and severe intracranial hemorrhage (ICH) for neonates receiving…
- Conditions
- Extracorporeal Life Support, Extracorporeal Membrane Oxygenation, Quality Improvement, Intracranial Hemorrhage
- Trial name
- NCT05075486
- Testing
- Collaborative quality improvement
- Sponsor
- Children's Hospital of Fudan University
Hemophilia A
UPLC-MS/MS Monitoring of Emicizumab Therapy
Emicizumab is a monoclonal bispecific antibody with a terminal half-life of 28 days which is now licensed in the treatment of severe haemophilia A with or without inhibitors.
- Trial name
- EMICARE (NCT04472169)
- Where
- 2 sites in France
- Volunteers
- 100 people
- Sponsor
- University Hospital, Lille
Intrapartum - Moderate and Severe Anaemia
World Maternal Antifibrinolytic Trial_2
Postpartum haemorrhage (PPH) is responsible for about 100,000 maternal deaths every year, almost all of which occur in low and middle income countries.
- Trial name
- WOMAN-2 (NCT03475342)
- Testing
- Tranexamic Acid
- Where
- 41 sites in Nigeria, Pakistan and 2 more
- Volunteers
- 15,068 people
- Sponsor
- London School of Hygiene and Tropical Medicine
Aneurysmal Subarachnoid Haemorrhage, World Neurosurgeon Federation Score ≥ III
Cardiac Function in Severe Aneurysmal Subarachnoid Haemorrhage Patients
Cardiac dysfunction can occur in aneurysmal subarachnoid haemorrhage and might impact patient's neurologic outcome Condition Aneurysmal subarachnoid haemorrhage World Neurosurgeon Federation Score ≥ III
- Trial name
- SPLASH (NCT01801800)
- Testing
- Echocardiography
- Where
- 2 sites in France
- Volunteers
- 80 people
- Sponsor
- Nantes University Hospital
Thrombotic Thrombocytopenic Purpura (TTP)
Expanded Access Program of TAK-755 for Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
The expanded access program allows people to gain access to unlicensed treatment on compassionate grounds. TAK-755 also known as rADAMTS13, is a medicine that treats people born with severe congenital or hereditary thrombotic…
- Trial name
- NCT05770219
- Testing
- TAK-755
- Sponsor
- Takeda
Gastric Cancer, Pancreatic Cancer
Study of Tranexamic Acid for Reducing Blood Requirement in Patients Undergoing Major Gastro-intestinal Surgery
Primary objective of the study is to compare requirement of blood transfusion and mortality in patients receiving Tranexamic acid (Cyklokapron®) and those not receiving it.
- Conditions
- Gastric Cancer, Pancreatic Cancer, Hepatocellular Cancer, Colon Cancer
- Trial name
- TMGS (NCT01655641)
- Testing
- Tranexamic acid, Standard of care
- Where
- Nepal
- Volunteers
- 118 people
- Sponsor
- Tribhuvan University Teaching Hospital, Institute Of Medicine.
Hemophilia A
Safety/Efficacy Study to Assess Whether FVIII/VWF Concentrate Can Induce Immune Tolerance in Haemophilia A Patients
The purpose of this study is to assess the role of a FVIII/VWF complex concentrate (Emoclot) in successfully inducing immune tolerance (I.T.I.) in patients with Haemophilia A with inhibitors, including patients at high risk of…
- Trial name
- ITI (NCT02479087)
- Testing
- Plasma-derived FVIII/VWF concentrate
- Where
- 4 sites in Egypt, India
- Volunteers
- 20 people
- Sponsor
- Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Intracranial Hemorrhages, Prematurity
Neurophysiology and Anatomy of Severe Intraventricular Hemorrhage (IVH)
Currently, when premature infants develop severe intraventricular hemorrhage (IVH), a type of intracerebral bleed, there are no proven therapeutic interventions to prevent the devastating consequences of this event.
- Trial name
- NCT00817310
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Vanderbilt University
Anemia, Hemolytic, Autoimmune, Felty Syndrome
Phase II Study of High-Dose Cyclophosphamide in Patients With Severe Autoimmune Hematologic Disease
OBJECTIVES: I. Determine the response rate and 1-year event-free survival in patients with severe autoimmune hematologic disease treated with high-dose cyclophosphamide.
- Conditions
- Anemia, Hemolytic, Autoimmune, Felty Syndrome, Purpura, Thrombocytopenic, Autoimmune Diseases
- Trial name
- NCT00010387
- Testing
- cyclophosphamide, filgrastim
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Johns Hopkins University